KR20230129996A - 탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법 - Google Patents

탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법 Download PDF

Info

Publication number
KR20230129996A
KR20230129996A KR1020237022781A KR20237022781A KR20230129996A KR 20230129996 A KR20230129996 A KR 20230129996A KR 1020237022781 A KR1020237022781 A KR 1020237022781A KR 20237022781 A KR20237022781 A KR 20237022781A KR 20230129996 A KR20230129996 A KR 20230129996A
Authority
KR
South Korea
Prior art keywords
chr7
mrna
sequence
cell
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022781A
Other languages
English (en)
Korean (ko)
Inventor
크리스티안 돔브로브스키
윌리암 프레드릭 해링턴
루안 올리베이라
Original Assignee
인텔리아 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인텔리아 테라퓨틱스, 인크. filed Critical 인텔리아 테라퓨틱스, 인크.
Publication of KR20230129996A publication Critical patent/KR20230129996A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005Cytidine deaminase (3.5.4.5)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00Reaction characterised by the enzymatic activity
    • C12Q2521/50Other enzymatic activities
    • C12Q2521/539Deaminase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237022781A 2020-12-11 2021-12-10 탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법 Pending KR20230129996A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063124060P 2020-12-11 2020-12-11
US63/124,060 2020-12-11
US202063130104P 2020-12-23 2020-12-23
US63/130,104 2020-12-23
US202163165636P 2021-03-24 2021-03-24
US63/165,636 2021-03-24
US202163275424P 2021-11-03 2021-11-03
US63/275,424 2021-11-03
PCT/US2021/062922 WO2022125968A1 (en) 2020-12-11 2021-12-10 Polynucleotides, compositions, and methods for genome editing involving deamination

Publications (1)

Publication Number Publication Date
KR20230129996A true KR20230129996A (ko) 2023-09-11

Family

ID=80118959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022781A Pending KR20230129996A (ko) 2020-12-11 2021-12-10 탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법

Country Status (13)

Country Link
US (1) US20240002820A1 (https=)
EP (1) EP4259792A1 (https=)
JP (1) JP2023553935A (https=)
KR (1) KR20230129996A (https=)
AU (1) AU2021394998A1 (https=)
CA (1) CA3205000A1 (https=)
CL (1) CL2023001684A1 (https=)
CO (1) CO2023009114A2 (https=)
CR (1) CR20230305A (https=)
IL (1) IL303506A (https=)
MX (1) MX2023006876A (https=)
TW (1) TW202237845A (https=)
WO (1) WO2022125968A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246266A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
WO2022261292A1 (en) * 2021-06-10 2022-12-15 Intellia Therapeutics, Inc. Modified guide rnas comprising an internal linker for gene editing
IL312507A (en) * 2021-11-03 2024-07-01 Intellia Therapeutics Inc Modified guide rnas for gene editing
CA3237303A1 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
EP4638783A2 (en) 2022-12-22 2025-10-29 Intellia Therapeutics, Inc. Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
WO2024227082A1 (en) * 2023-04-26 2024-10-31 Vijay Sankaran Base-editing perturbation screens and uses thereof
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025038642A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying cd70
WO2025081064A2 (en) * 2023-10-11 2025-04-17 Illumina, Inc. Thermophilic deaminase and methods for identifying modified cytosine
WO2025078604A1 (en) * 2023-10-13 2025-04-17 Smartcella Solutions Ab Methods and compositions for delivery of unmodified mrna constructs using mesenchymal stem cells
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025137439A2 (en) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Engineered t cells
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy
WO2026006390A2 (en) * 2024-06-26 2026-01-02 Intellia Therapeutics, Inc. Modified guide rnas for genome editing

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JP3131222B2 (ja) 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する2′修飾オリゴヌクレオチド
JPH10500310A (ja) 1994-05-19 1998-01-13 ダコ アクティーゼルスカブ 淋菌及びトラコーマ クラミジアの検出のためのpna プローブ
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
CN107879960B (zh) 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
CN120842296A (zh) 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
LT3436077T (lt) 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
KR20180134412A (ko) 2016-04-22 2018-12-18 인텔리아 테라퓨틱스, 인크. 전사 인자 4에서 트라이뉴클레오타이드 반복부와 연관된 질환의 치료를 위한 조성물 및 방법
SG10202106058WA (en) 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
TWI851534B (zh) 2016-12-22 2024-08-11 美商英特利亞醫療公司 用於治療α-1抗胰蛋白酶缺乏症之組合物及方法
WO2019041296A1 (zh) * 2017-09-01 2019-03-07 上海科技大学 一种碱基编辑系统及方法
US20230140670A1 (en) 2017-09-29 2023-05-04 Intellia Therapeutics, Inc. Formulations
EP3688161A1 (en) 2017-09-29 2020-08-05 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating attr amyloidosis
AU2019282824C1 (en) 2018-06-08 2026-04-23 Intellia Therapeutics, Inc. Modified guide RNAS for gene editing
MX2021001070A (es) 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
AU2019326408A1 (en) * 2018-08-23 2021-03-11 Sangamo Therapeutics, Inc. Engineered target specific base editors
US20220009878A1 (en) 2018-10-02 2022-01-13 Intellia Therapeutics, Inc. Ionizable amine lipids
IL282267B2 (en) 2018-10-15 2026-03-01 Univ Massachusetts Programmed DNA editing by chimeric deaminase-nme2cas9 proteins
BR112021010853A2 (pt) 2018-12-05 2021-08-31 Intellia Therapeutics, Inc. Lipídios de amina modificados
EP3911735A4 (en) * 2019-01-16 2023-07-12 Beam Therapeutics, Inc. MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION
AU2020248337A1 (en) * 2019-03-28 2021-11-04 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
CN114127044A (zh) 2019-04-25 2022-03-01 英特利亚治疗股份有限公司 可电离的胺类脂质和脂质纳米颗粒

Also Published As

Publication number Publication date
CO2023009114A2 (es) 2023-08-18
CL2023001684A1 (es) 2024-01-05
WO2022125968A1 (en) 2022-06-16
MX2023006876A (es) 2023-07-31
CA3205000A1 (en) 2022-06-16
IL303506A (en) 2023-08-01
EP4259792A1 (en) 2023-10-18
CR20230305A (es) 2023-11-10
TW202237845A (zh) 2022-10-01
AU2021394998A9 (en) 2024-05-02
JP2023553935A (ja) 2023-12-26
AU2021394998A1 (en) 2023-06-29
US20240002820A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
KR20230129996A (ko) 탈아미노화를 포함하는 게놈 편집을 위한 폴리뉴클레오타이드,조성물 및 방법
AU2019250224B2 (en) Enhanced transgene expression and processing
AU2022200903C1 (en) Engineered Cascade components and Cascade complexes
KR102724029B1 (ko) 포유동물 세포의 특성을 변경하기 위한 인공 마이크로-rna 및 이들 생성물의 조성물을 사용한 포유동물 세포의 변형
DK2753355T3 (en) ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF
KR20210143230A (ko) 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
KR20200058509A (ko) Attr 아밀로이드증의 ttr 유전자 편집 및 치료를 위한 조성물 및 방법
AU2016373365B2 (en) Transposon system, kit comprising the same, and uses thereof
JP2020535805A (ja) 細胞の遺伝子修飾のための非組込みdnaベクター
CN115362256A (zh) 用于激肽释放酶(klkb1)基因编辑的组合物和方法
KR20220004984A (ko) Ttr 유전자 편집을 위한 조성물 및 방법 및 코르티코스테로이드를 포함하는 attr 아밀로이드증의 치료 또는 그의 용도
TW202309034A (zh) Dna依賴性蛋白質激酶抑制劑以及其組合物及用途
KR20220004649A (ko) 폴리펩티드 발현을 위한 폴리뉴클레오티드, 조성물 및 방법
KR20240029020A (ko) Dna 변형을 위한 crispr-트랜스포손 시스템
AU2023265204A1 (en) Virus-derived construct plasmid library and construction of same
KR20110106392A (ko) 동물세포를 사용해서 외래유전자 유래 단백질을 대량으로 생산하기 위한 발현 벡터, 및 그의 이용
CN114045305B (zh) 多转座子系统
CN116171326A (zh) 用于基因病症的核酸疗法
US20240228577A1 (en) Programmed Cell Death Protein 1 (PD1) Compositions and Methods for Cell-Based Therapy
RU2827658C2 (ru) Сконструированные компоненты cascade и комплексы cascade
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade
WO2025080985A1 (en) Tissue specific anellovector delivery
HK40103611A (zh) 用於免疫疗法的自然杀伤细胞受体2b4组合物和方法
HK40096021A (zh) 用於免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法
WO2025064834A1 (en) Isolated betacoronavirus ires sequences

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241210

Comment text: Request for Examination of Application